Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals on $2.5M Registered Direct Offering
August 4, 2015 – Press Release – New York, NY – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biopharmaceutical company focused on developing and commercializing cancer therapies, in a registered direct offering. DelMar accepted subscriptions from institutional and accredited investors and approximately 4.0 million common stock and warrants for an aggregate price of $2.5 million. Each common share had a purchase price of $0.60 per share. The warrants had an exercise price of $0.75 per share.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, David Manno and Associate Jeffrey Cahlon.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Founding Partner Gregory Sichenzia Featured in Business Insider Discussing the Legal Aftermath for Tesla - September 19, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for AusCann Group Holdings Ltd on OTCQX Listing - September 15, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for Zelda Therapeutics Ltd on OTCQX Listing - September 15, 2018